Preclinical studies from our group and others have shown that, in the context of TP53 inactivation, therapeutic agents specifically targeting the MDM2/p53 interaction such as nutlin and RITA have limited anti-cancer activity [9]. The gene discussed is TP53; the disease is cancer.